نتائج البحث

Testing the Addition of Trastuzumab or Trastuzumab/Pertuzumab to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma

• Authors : NRG Oncology

• Source: A Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined With Either Trastuzumab and Hyaluronidase-oysk (HERCEPTIN HYLECTA) or Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf (PHESGO) in HER2

تفاصيل العنوان

Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma) (DICE)

• Authors : Takeda Pharmaceuticals International, Inc.; North Eastern German Society of Gynaecological Oncology

• Source: An International Multi-centre Randomised Phase II Study to Assess the Efficacy of TAK228 in Combination With Intravenous Weekly Paclitaxel Compared With Weekly Paclitaxel Alone in Women With

تفاصيل العنوان

Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib (ROCSAN)

• Authors : Tesaro, Inc.

• Source: An International Multicentric Randomized Phase II Evaluating Dostarlimab in Combination With Niraparib Versus Niraparib Alone Compared to Chemotherapy in the Treatment of Metastatic or Recurrent

تفاصيل العنوان

A Study of Pembrolizumab and Olaparib in People With Endometrial Cancer or Endometrial Carcinosarcoma

• Authors : Merck Sharp & Dohme LLC

• Source: A Phase II Trial of Pembrolizumab Plus Olaparib for the Treatment of Patients With Persistent/Recurrent Endometrial Cancers

تفاصيل العنوان

A Study of Pembrolizumab With Lenvatinib in Women With Advanced Uterine Carcinosarcoma

• Authors : Merck Sharp & Dohme LLC

• Source: A Phase II Trial of Pembrolizumab Plus Lenvatinib for the Treatment of Patients With Advanced Uterine and Ovarian Carcinosarcomas

تفاصيل العنوان

Next-generation sequencing analysis and TP53 mutation in a rare case of fallopian tube carcinosarcoma.

• Authors : Yoon Young Jeong¹; Sun-Jae Lee²; Jung Min Ryu¹

• Source: European Journal of Gynaecological Oncology. Aug2024, Vol. 45 Issue 4, p177-181. 5p.

تفاصيل العنوان

Study of BMS-986205 and Nivolumab in Endometrial Cancer or Endometrial Carcinosarcoma That Has Not Responded to Treatment

• Authors : Bristol-Myers Squibb

• Source: A Phase II Trial of IDO-Inhibitor, BMS-986205, and PD-1 Inhibitor, Nivolumab, in Patients With Recurrent or Persistent Endometrial Cancer or Endometrial Carcinosarcomas (CA017-056)

تفاصيل العنوان

EPOCH: Eribulin and Pembrolizumab in Ovarian/Uterine Carcinosarcoma (EPOCH)

• Authors : Eisai Inc.; Merck Sharp & Dohme LLC

• Source: The EPOCH Study: Phase II Open Labelled Study Investigating the Use of Single Agent Eribulin and Eribulin in Combination With Pembrolizumab in Relapsed Tubo-ovarian or Uterine

تفاصيل العنوان

Strategic multidisciplinary management of pelvic carcinosarcoma: Emphasizing advanced diagnostic imaging and staged surgical interventions

• Authors : Mena Louis, DO; Nathaniel Grabill, MD; Mariah Cawthon, MD

Subjects: Pelvic carcinosarcoma; Advanced imaging; MRI

• Source: Radiology Case Reports, Vol 19, Iss 10, Pp 4583-4598 (2024)

تفاصيل العنوان

Prognostic Nomogram for Predicting Survival, Clinicopathological Analysis, and Racial Disparities in Uterine Carcinosarcoma: A Retrospective Population-Based Study

• Authors : Asad Ullah; Lily Rubin; Alexa Rakusin

Subjects: uterine carcinosarcoma; SEER; cause-specific survival

• Source: Surgeries, Vol 5, Iss 3, Pp 743-757 (2024)

تفاصيل العنوان